ALPMY News and Press, Astellas Pharma Inc. ADR From 09/28/19

Stock Information

Company Name:	Astellas Pharma Inc. ADR
Stock Symbol:	ALPMY
Market:	OTC

ALPMY ALPMY Quote ALPMY Short ALPMY News ALPMY Articles ALPMY Message Board

Get ALPMY Alerts

News, Short Squeeze, Breakout and More Instantly...

Email Address

ALPMY - Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer

BOTHELL, Wash. and TOKYO , Sept. 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced initial results from the phase 1 clinical trial EV-103. Forty-f...

ALPMY - Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

TOKYO , Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion reco...

ALPMY - Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

TOKYO and SAN FRANCISCO , Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A Schoeneck., "FibroGen") today announced that Japan's Ministry of Health, Labour and ...

ALPMY - Frequency Therapeutics Files For IPO For Hearing Loss Drug

Quick Take Frequency Therapeutics ( FREQ ) has filed to raise gross proceeds of up to $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics focused on repairing or reversing damage caused by a range of degenerative diseases. FREQ ...

ALPMY - Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

BOTHELL, Wash. and TOKYO , Sept. 16, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics Lic...

ALPMY - Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

MENLO PARK, Calif. , Sept. 11, 2019 /PRNewswire/ -- Astellas Venture Management, LLC (President: Shunichiro Matsumoto , Ph.D., MBA, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas"), and Miss...

ALPMY - U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

TOKYO and NEW YORK , Aug. 21, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemen...

ALPMY - Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

TOKYO , Aug. 6, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced dosing of the first patient in the SKYLIGHT 1™ Phase 3 pivotal trial for fezolinetant, an investigational oral, non-hormonal compo...

ALPMY - IVA Worldwide Fund Class A Q2 2019 Investor Letter